Multicenter Nested Case-Control Study

A standard multicenter case-control recruits incident cases from hospital or clinic records and selects controls from the general population at the time of analysis, making it susceptible to selection and recall bias. A multicenter nested case-control embeds the case-control within pre-existing cohorts: both cases and controls come from the same defined cohort population, exposure data were collected prospectively before the outcome occurred, and controls are sampled from the risk set at the case's index date. This preserves temporality and eliminates many sources of bias present in conventional case-control studies.

Conditional logistic regression is the standard approach; it conditions on the matched set (case plus its controls), so center and other matched factors are automatically controlled. When matching is on many variables or centers differ substantially, a stratified Cox model on the full cohort may be preferred. For two-stage analyses, center-specific odds ratios are computed first, then combined using fixed-effects or random-effects meta-analysis.

Statistical efficiency increases rapidly from 1:1 to about 1:4 matching (four controls per case) and plateaus thereafter. For rare outcomes and expensive assays, 1:2 or 1:3 is typically a cost-efficient compromise. The optimal ratio should be determined by a formal power calculation that accounts for the matching and center stratification.

Yes. When data sharing is legally or ethically constrained, a two-stage federated approach is valid: each center runs its own conditional logistic regression and reports summary statistics (log-odds ratios and standard errors), which are then pooled using meta-analytic methods at the coordinating center. This preserves data privacy but may lose some efficiency compared to individual participant data pooling, especially when sample sizes per center are small.

Each participating center typically requires its own institutional ethics approval referencing the multicenter consortium protocol. Data transfer agreements must comply with applicable regulations (e.g., GDPR in Europe, HIPAA in the US). Biobank access policies, consent scope for secondary use, and authorship or data-sharing agreements should be negotiated and documented before the study begins to avoid delays at the analysis stage.